Skip to main content
SpringerLink
Log in

Non-Hodgkin’s Lymphoma in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The expansion of older population segments and the continuous increase in the incidence of non-Hodgkin’s lymphoma (NHL) makes this group of neoplasms an important and growing problem. Older NHL patients have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. A functional assessment of the elderly patient is necessary to determine the likelihood of tolerating and responding to therapy. The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and aids in identification of subjects who will or will not benefit from anti-neoplastic treatment.

Although indolent lymphomas present more frequently at advanced stage, randomized trials do not show better outcomes with early therapy, supporting close observation until specific therapeutic indications arise. Use of the monoclonal antibody rituximab as a single agent or in combination with chemotherapy improves survival and has become the standard of care in first-line treatment. Radioimmunoconjugates, bendamustine, and other monoclonal antibodies as well as novel targeted agents also are active against indolent lymphomas. Diffuse large B-cell lymphoma is an aggressive but potentially curable disease. Several trials performed exclusively in elderly patients have demonstrated improved response rates and survival with the addition of rituximab to CHOP (cyclophosphamide, doxorubicin [adriamycin], vincristine, prednisone) chemotherapy in the front-line setting. Salvage chemotherapy followed by autologous haematopoietic cell transplant (autoHCT) has been shown to have better failure-free and overall survival in randomized trials involving younger patients. Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Horner MJ, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975–2006. National Cancer Institute [online]. Available from: http://seer.cancer.gov/csr/1975_2006/ [Accessed 2009 Jul 5]

  2. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000 Aug 2; 92(15): 1240–51

    Article  PubMed  CAS  Google Scholar 

  3. Clarke CA, Glaser SL. Changing incidence of non-Hodg-kin lymphomas in the United States. Cancer 2002 Apr 1; 94(7): 2015–23

    Article  PubMed  Google Scholar 

  4. Lichtman SM. Aggressive lymphoma in the elderly. Crit Rev Oncol Hematol 2000 Feb; 33(2): 119–28

    Article  PubMed  CAS  Google Scholar 

  5. Morrison VA. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2008 Oct; 8(10): 1651–8

    Article  PubMed  CAS  Google Scholar 

  6. Droz JP, Aapro M, Balducci L. Overcoming challenges associated with chemotherapy treatment in the senior adult population. Crit Rev Oncol Hematol 2008; 68Suppl. 1: S1–8

    Article  PubMed  Google Scholar 

  7. Dupuis J, Haioun C. Non-Hodgkin lymphoma in the elderly [in French]. Bull Cancer 2008; 95 FMC Onco: F79–83

    PubMed  Google Scholar 

  8. NCCN clinical practice guidelines in oncology: senior adult oncology. Version 1.2009. Fort Washington PA): National Comprehensive Cancer Network, 2009 Feb 9

  9. Zwick C, Gleissner B, Pfreundschuh M. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma. Clin Lymphoma Myeloma 2007 Dec; 8Suppl. 2: S43–9

    Article  PubMed  CAS  Google Scholar 

  10. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14): 987–94

    Google Scholar 

  11. Sonnen R, Schmidt WP, Müller-Hermelink HK, et al. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129(3): 366–72

    Article  PubMed  Google Scholar 

  12. Sehn L, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109(5): 1857–61

    Article  PubMed  CAS  Google Scholar 

  13. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004 Nov 1; 22(21): 4302–11

    Article  PubMed  CAS  Google Scholar 

  14. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986 Mar; 4(3): 295–305

    PubMed  CAS  Google Scholar 

  15. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004 Aug 1; 104(3): 634–41

    Article  PubMed  CAS  Google Scholar 

  16. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004 Aug 1; 104(3): 626–33

    Article  PubMed  CAS  Google Scholar 

  17. Extermann M, Albrand G, Chen H, et al. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 2003 Sep 1; 21(17): 3214–9

    Article  PubMed  Google Scholar 

  18. John V, Mashru S, Lichtman S. Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging 2003: 737–59

    Google Scholar 

  19. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 2003; 42(9): 779–91

    Article  PubMed  CAS  Google Scholar 

  20. Vestal RE. Aging and pharmacology. Cancer 1997 Oct 1; 80(7): 1302–10

    Article  PubMed  CAS  Google Scholar 

  21. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996 Jul; 31(1): 47–64

    Article  PubMed  CAS  Google Scholar 

  22. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993 Feb; 20(1): 43–9

    PubMed  CAS  Google Scholar 

  23. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999 Sep–Oct; 45(5): 243–53

    Article  PubMed  CAS  Google Scholar 

  24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41

    Article  PubMed  CAS  Google Scholar 

  25. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 Nov; 7(11): 1748–56

    PubMed  CAS  Google Scholar 

  26. Spruill WJ, Wade WE, Cobb 3rd HH. Estimating glomerular filtration rate with a modification of diet in renal disease equation: implications for pharmacy. Am J Health Syst Pharm 2007 Mar 15; 64(6): 652–60

    Article  PubMed  Google Scholar 

  27. Spruill WJ, Wade WE, Cobb 3rd HH. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother 2008 Aug; 6(3): 153–60

    Article  PubMed  Google Scholar 

  28. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000 Apr; 18(7): 1412–22

    PubMed  CAS  Google Scholar 

  29. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001 Jun; 2(1): 47–56

    Article  PubMed  CAS  Google Scholar 

  30. Chrischilles E, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control 2002 May-Jun; 9(3): 203–11

    PubMed  Google Scholar 

  31. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin’s lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999 Jul 1; 94(1): 33–8

    PubMed  CAS  Google Scholar 

  32. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995 Oct; 13(10): 2530–9

    PubMed  CAS  Google Scholar 

  33. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or =70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998 Jan; 16(1): 27–34

    PubMed  CAS  Google Scholar 

  34. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival. Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol 1997 Aug; 15(8): 2945–53

    PubMed  CAS  Google Scholar 

  35. Lyman GH, Kuderer N, Agboola O, et al. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003 Nov-Dec; 10(6): 487–99

    PubMed  Google Scholar 

  36. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998 Jul; 16(7): 2352–8

    PubMed  CAS  Google Scholar 

  37. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003 Aug 15; 21(16): 3041–50

    Article  PubMed  CAS  Google Scholar 

  38. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003 May 15; 101(10): 3840–8

    Article  PubMed  CAS  Google Scholar 

  39. Bohlius J, Reiser M, Schwarzer G, et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003 Aug; 122(3): 413–23

    Article  PubMed  CAS  Google Scholar 

  40. Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189

  41. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007 Jul 20; 25(21): 3158–67

    Article  PubMed  CAS  Google Scholar 

  42. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan 24; 346(4): 235–42

    Article  PubMed  CAS  Google Scholar 

  43. Habermann T. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19): 3121–7

    Article  PubMed  CAS  Google Scholar 

  44. Lin PC, Hsiao LT, Poh SB, et al. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol 2007 Feb; 86(2): 95–100

    Article  PubMed  CAS  Google Scholar 

  45. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 Jul 1; 24(19): 3187–205

    Article  PubMed  CAS  Google Scholar 

  46. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006 Oct; 42(15): 2433–53

    Article  PubMed  CAS  Google Scholar 

  47. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyl-daunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976 Oct; 38(4): 1484–93

    Article  PubMed  CAS  Google Scholar 

  48. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993 Apr 8; 328(14): 1002–6

    Article  PubMed  CAS  Google Scholar 

  49. Grann VR, Hershman D, Jacobson JS, et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 2006 Oct 1; 107(7): 1530–41

    Article  PubMed  CAS  Google Scholar 

  50. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998 Sep 24; 339(13): 900–5

    Article  PubMed  CAS  Google Scholar 

  51. Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008 Jul 1; 26(19): 3159–65

    Article  PubMed  CAS  Google Scholar 

  52. Kouroukis CT, Browman GP, Esmail R, et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 2002 Jan 15; 136(2): 144–52

    PubMed  CAS  Google Scholar 

  53. Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007; 14(1): 44–56

    PubMed  Google Scholar 

  54. Repetto L, Venturino A, Fratino L, et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 2003; 39(7): 870–80

    Article  PubMed  CAS  Google Scholar 

  55. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55(3): 241–52

    Article  PubMed  Google Scholar 

  56. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007; 14(1): 7–12

    PubMed  Google Scholar 

  57. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20(2): 494–502

    Article  PubMed  Google Scholar 

  58. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001: 1691–9

    Google Scholar 

  59. Bergland A, Laake K. Concurrent and predictive validity of “getting up from lying on the floor”. Aging Clin Exp Res 2005 Jun; 17(3): 181–5

    PubMed  Google Scholar 

  60. Ingram SS, Seo PH, Martell RE, et al. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol 2002 Feb 1; 20(3): 770–5

    Article  PubMed  Google Scholar 

  61. Lachs MS, Feinstein AR, Cooney Jr LM, et al. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 1990 May 1; 112(9): 699–706

    PubMed  CAS  Google Scholar 

  62. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005 Nov 1; 104(9): 1998–2005

    Article  PubMed  Google Scholar 

  63. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997 Jun 1; 89(11): 3909–18

    Google Scholar 

  64. McLaughlin P. The indolent B-cell lymphomas. In: Leonard JP, Coleman M, editors. Hodgkin and non-Hodgkin lymphoma cancer treatment and research. New York: Springer, 2006: 89–120

    Chapter  Google Scholar 

  65. Morrison VA. Non-Hodgkin’s lymphoma in the elderly. Part 1: overview and treatment of follicular lymphoma. Oncology (Williston Park) 2007 Aug; 21(9): 1104–10

    Google Scholar 

  66. Tan D, Horning SJ. Follicular lymphoma: clinical features and treatment. Hematol Oncol Clin North Am 2008 Oct; 22(5): 863–82, viii

    Article  PubMed  Google Scholar 

  67. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–26

    Article  PubMed  Google Scholar 

  68. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–52

    Article  PubMed  CAS  Google Scholar 

  69. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–9

    Article  PubMed  Google Scholar 

  70. Garvin AJ, Simon RM, Osborne CK, et al. An autopsy study of histologic progression in non-Hodgkin’s lymphomas: 192 cases from the National Cancer Institute. Cancer 1983 Aug 1; 52(3): 393–8

    Article  PubMed  CAS  Google Scholar 

  71. Yuen AR, Kamel OW, Halpern J, et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995 Jul; 13(7): 1726–33

    PubMed  CAS  Google Scholar 

  72. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996 Apr; 14(4): 1282–90

    CAS  Google Scholar 

  73. Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone [abstract]. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 2004 Jul 15; 22(14 Suppl.): 6521

    Google Scholar 

  74. Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001 Dec 1; 51(5): 1219–27

    Article  PubMed  CAS  Google Scholar 

  75. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006 Mar 1; 64(3): 928–34

    Article  PubMed  Google Scholar 

  76. Pendlebury S, el Awadi M, Ashley S, et al. Radiotherapy results in early stage low grade nodal non-Hodgkin’s lymphoma. Radiother Oncol 1995 Sep; 36(3): 167–71

    Article  PubMed  CAS  Google Scholar 

  77. Tezcan H, Vose JM, Bast M, et al. Limited stage I and II follicular non-Hodgkin’s lymphoma: the Nebraska Lymphoma Study Group experience. Leuk Lymphoma 1999 Jul; 34(3-4): 273–85

    PubMed  CAS  Google Scholar 

  78. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004 Apr 15; 22(8): 1454–9

    Article  PubMed  Google Scholar 

  79. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma International Prognostic Index. Blood 2004 Sep 1; 104(5): 1258–65

    Article  PubMed  CAS  Google Scholar 

  80. Hiddemann W, Buske C, Dreyling M, et al. Current management of follicular lymphomas. Br J Haematol 2007 Jan; 136(2): 191–202

    Article  PubMed  CAS  Google Scholar 

  81. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984 Dec 6; 311(23): 1471–5

    Article  PubMed  CAS  Google Scholar 

  82. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009 Mar 10; 27(8): 1202–8

    Article  PubMed  Google Scholar 

  83. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997 Mar; 15(3): 1110–7

    PubMed  CAS  Google Scholar 

  84. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003 Aug 16; 362(9383): 516–22

    Article  PubMed  CAS  Google Scholar 

  85. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting vs aggressive combined modality treatment. Semin Hematol 1988 Apr; 25 (2 Suppl. 2): 11–6

    PubMed  CAS  Google Scholar 

  86. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer And Leukemia Group B. J Clin Oncol 2003 Jan 1; 21(1): 5–15

    Article  PubMed  CAS  Google Scholar 

  87. Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin’s lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5Suppl. 2: 67–71

    Article  PubMed  Google Scholar 

  88. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 Aug; 16(8): 2825–33

    PubMed  CAS  Google Scholar 

  89. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001 Jan 1;97(1): 101–6

    Article  PubMed  CAS  Google Scholar 

  90. Hainsworth JD, Litchy S, Burris 3rd HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002 Oct 15; 20(20): 4261–7

    Article  PubMed  CAS  Google Scholar 

  91. Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002 Feb; 29 (1 Suppl. 2): 25–9

    Article  PubMed  CAS  Google Scholar 

  92. Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin’s lymphoma. Semin Oncol 2003 Feb; 30 (1 Suppl. 2): 9–15

    Article  PubMed  CAS  Google Scholar 

  93. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004 Nov 15; 104(10): 3064–71

    Article  PubMed  CAS  Google Scholar 

  94. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec 1; 106(12): 3725–32

    Article  PubMed  CAS  Google Scholar 

  95. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005 Feb 15; 105(4): 1417–23

    Article  PubMed  CAS  Google Scholar 

  96. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 Oct 1; 26(28): 4579–86

    Article  PubMed  CAS  Google Scholar 

  97. Salles GA, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final analysis of the GELAGOELAMS FL2000 Study with a 5-year follow-up [abstract]. Blood 2007; 110(11): 792

    Google Scholar 

  98. Rivas-Vera S, Baez E, Sobrevilla-Calvo P, et al. Is first line single agent rituximab the best treatment for indolent non-Hodgkin’s lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP [abstract no. 2431]. Blood 2005; 106(11): 684a

    Google Scholar 

  99. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007 May 20; 25(15): 1986–92

    Article  PubMed  CAS  Google Scholar 

  100. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006 Nov 15; 108(10): 3295–301

    Article  PubMed  CAS  Google Scholar 

  101. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007: 706–14

    Google Scholar 

  102. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma. A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005 Feb 20; 23(6): 1088–95

    Article  PubMed  CAS  Google Scholar 

  103. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009 Apr 1; 27(10): 1607–14

    Article  PubMed  CAS  Google Scholar 

  104. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 Dec 15; 108(13): 4003–8

    Article  PubMed  CAS  Google Scholar 

  105. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009 Feb 18; 101(4): 248–55

    Article  PubMed  CAS  Google Scholar 

  106. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005 May 20; 23(15): 3383–9

    Article  PubMed  CAS  Google Scholar 

  107. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009 Mar 20; 27(9): 1492–501

    Article  PubMed  CAS  Google Scholar 

  108. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008 Jan 1; 14(1): 309–17

    Article  PubMed  CAS  Google Scholar 

  109. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002 Jan; 87(1): 33–43

    PubMed  CAS  Google Scholar 

  110. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008 Sep 20; 26(27): 4473–9

    Article  PubMed  CAS  Google Scholar 

  111. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood 2007; 110(11): 385

    Google Scholar 

  112. O’Connor OA, Czuczman MS. Novel approaches for the treatment of NHL: proteasome inhibition and immune modulation. Leuk Lymphoma 2008; 49Suppl. 1: 59–66

    Article  PubMed  CAS  Google Scholar 

  113. Witzig TE, Vose J, Pietronigro D, et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma [abstract]. J Clin Oncol 2007 Jun 20; 25(sn18 Suppl.): 8066

    Google Scholar 

  114. Witzig TE, Wiernik PH, Moore T, et al. Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma: final results of NHL-001 [abstract]. J Clin Oncol 2009 May 20; 27(15 Suppl.): 8560

    Google Scholar 

  115. Fowler NH, McLaughlin P, Kwak L, et al. Lenalidomide and rituximab for untreated indolent non-Hodgkin’s lymphoma [abstract]. J Clin Oncol 2009 May 20; 27(15 Suppl.): 8548

    Google Scholar 

  116. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008 Mar 20; 26(9): 1544–52

    Article  PubMed  CAS  Google Scholar 

  117. Taylor RP, Pawluczkowycz AW, Lindorfer MA, et al. Binding of submaximal C1q to B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX) promotes complement dependent cytotoxicity (CDC), and considerably higher levels of CDC are induced by OFA than by RTX [abstract]. Blood 2008; 112(11): 1578

    Google Scholar 

  118. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 2008 Feb 1; 111(3): 1094–100

    Article  PubMed  CAS  Google Scholar 

  119. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008 Jun 15; 111(12): 5486–95

    Article  PubMed  CAS  Google Scholar 

  120. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003 Aug 15; 21(16): 3051–9

    Article  PubMed  CAS  Google Scholar 

  121. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 2006 Aug 20; 24(24): 3880–6

    Article  PubMed  CAS  Google Scholar 

  122. Leonard JP, Martin P, Ruan J, et al. New monoclonal antibodies for non-Hodgkin’s lymphoma. Ann Oncol 2008 Jun; 19Suppl. 4: iv60–2

    Article  PubMed  Google Scholar 

  123. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008 Aug 7; 359(6): 613–26

    Article  PubMed  CAS  Google Scholar 

  124. Elstrom RL, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematol Oncol Clin North Am 2008 Oct; 22(5): 1037–49, x–xi

    Article  PubMed  Google Scholar 

  125. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005 Jul 1; 23(19): 4390–8

    Article  PubMed  CAS  Google Scholar 

  126. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007 Jul; 18(7): 1216–23

    Article  PubMed  CAS  Google Scholar 

  127. Czuczman J, Johnson J, Jung S, et al. A phase II trial of extended induction galiximab ([G] Anti CD80 Monoclonal Antibody) plus rituximab in previously untreated follicular lymphoma: initial report of CALGB 50402 [abstract]. Ann Oncol 2008; 19Suppl. 4: iv130

    Google Scholar 

  128. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002 Aug 1; 20(15): 3262–9

    Article  PubMed  CAS  Google Scholar 

  129. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002 Jun 15; 99(12): 4336–42

    Article  PubMed  CAS  Google Scholar 

  130. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2004 Apr 15; 22(8): 1469–79

    Article  PubMed  CAS  Google Scholar 

  131. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002 May 15; 20(10): 2453–63

    Article  PubMed  CAS  Google Scholar 

  132. Lemieux B, Coiffier B. Radio-immunotherapy in low-grade non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol 2005 Mar; 18(1): 81–95

    Article  PubMed  Google Scholar 

  133. Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2009 May; 23(3): 137–42

    Article  PubMed  CAS  Google Scholar 

  134. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009 Sep;9(9):675–81

    Article  PubMed  CAS  Google Scholar 

  135. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992 Oct 22; 327(17): 1209–15

    Article  PubMed  CAS  Google Scholar 

  136. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 1997 May 1; 89(9): 3129–35

    PubMed  CAS  Google Scholar 

  137. Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, et al. Prolonged idiotypic vaccination against follicular lymphoma. Leuk Lymphoma 2009 Jan; 50(1): 47–53

    Article  PubMed  CAS  Google Scholar 

  138. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006 Sep 20;98(18): 1292–301

    Article  PubMed  Google Scholar 

  139. Levy R, Robertson M, Ganjoo K, et al. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin’s lymphoma (fNHL) [abstract no. LB-204]. AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA)

  140. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009 Jun 20; 27(18): 3036–43

    Article  PubMed  CAS  Google Scholar 

  141. Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results [abstract no. 2]. J Clin Oncol 2009; 27 Suppl.: 18s

    Article  Google Scholar 

  142. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001 Jan 15; 97(2): 404–9

    Article  PubMed  CAS  Google Scholar 

  143. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998 Jan; 16(1): 13–8

    PubMed  CAS  Google Scholar 

  144. Voso MT, Martin S, Hohaus S, et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 2000 May; 25(9): 957–64

    Article  PubMed  CAS  Google Scholar 

  145. Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and auto-grafting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002 Aug 13; 100(5): 1559–65

    Article  PubMed  CAS  Google Scholar 

  146. Seyfarth B, Kuse R, Sonnen R, et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol 2001 Jul; 80(7): 398–405

    Article  PubMed  CAS  Google Scholar 

  147. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104(9): 2667–74

    Article  PubMed  CAS  Google Scholar 

  148. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005 May 15; 105(10): 3817–23

    Article  PubMed  CAS  Google Scholar 

  149. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 2006 Oct 15; 108(8): 2540–4

    Article  PubMed  CAS  Google Scholar 

  150. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003 Nov1; 21(21): 3918–27

    Article  PubMed  CAS  Google Scholar 

  151. Barr PM, Lazarus HM. Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. Curr Opin Oncol 2008 Sep; 20(5): 502–8

    Article  PubMed  Google Scholar 

  152. Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007 Nov;21(11): 2324–31

    Article  PubMed  CAS  Google Scholar 

  153. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007 Jun 20; 25(18): 2554–9

    Article  PubMed  Google Scholar 

  154. Kang TY, Rybicki LA, Bolwell BJ, et al. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 2007 Nov; 40(10): 973–8

    Article  PubMed  CAS  Google Scholar 

  155. Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001 Mar; 27(6): 593–9

    Article  PubMed  CAS  Google Scholar 

  156. Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation Registry. Haematologica 2008 Dec; 93(12): 1837–42

    Article  PubMed  Google Scholar 

  157. Morrison VA. Non-Hodgkin’s lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas. Oncology (Williston Park) 2007 Sep; 21(10): 1191–8; discussion 8-208, 210

    Google Scholar 

  158. O’Reilly SE, Connors JM, Macpherson N, et al. Malignant lymphomas in the elderly. Clin Geriatr Med 1997 May; 13(2): 251–63

    PubMed  Google Scholar 

  159. Balducci L, Ballester OF. Non-Hodgkin’s lymphoma in the elderly. Cancer Control 1996 Oct; 3 (5 Suppl. 1): 5–14

    PubMed  Google Scholar 

  160. Ng AK. Diffuse large B-cell lymphoma. Semin Radiat Oncol 2007 Jul; 17(3): 169–75

    Article  PubMed  Google Scholar 

  161. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998 Jul 2; 339(1): 21–6

    Article  PubMed  CAS  Google Scholar 

  162. Miller TP, LeBlanc M, Spier CM, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin lymphomas: update of the South-west Oncology Group (SWOG) randomized trial. Blood 2001; 98: 724a–5a

    Article  Google Scholar 

  163. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007 Mar 1; 25(7): 787–92

    Article  PubMed  CAS  Google Scholar 

  164. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005 Mar 24; 352(12): 1197–205

    Article  PubMed  CAS  Google Scholar 

  165. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 May; 7(5): 379–91

    Article  PubMed  CAS  Google Scholar 

  166. Miller TP, Unger JM, Spier C, et al. Effect of adding rituximab to three cycles of CHOP plus invoved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014) [abstract]. Blood 2004; 104(11): A–158

    Google Scholar 

  167. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004 Aug 1; 22(15): 3032–8

    Article  PubMed  CAS  Google Scholar 

  168. Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004 Aug 1; 22(15): 2982–4

    Article  PubMed  Google Scholar 

  169. Friedberg JW. Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol 2006 May; 7(5): 357–9

    Article  PubMed  Google Scholar 

  170. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001 Jan 15; 19(2): 389–97

    PubMed  CAS  Google Scholar 

  171. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005 Jun 20; 23(18): 4117–26

    Article  PubMed  CAS  Google Scholar 

  172. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 Jul 1; 24(19): 3121–7

    Article  PubMed  CAS  Google Scholar 

  173. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008 Feb; 9(2): 105–16

    Article  PubMed  CAS  Google Scholar 

  174. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009 Apr 23; 113(17): 3896–902

    Article  PubMed  CAS  Google Scholar 

  175. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin’s lymphoma. J Clin Oncol (Meeting Abstracts) 2009 May 20; 27(15S): 8506

    Google Scholar 

  176. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest 2006 Oct; 24(6): 593–600

    Article  PubMed  CAS  Google Scholar 

  177. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994 Jun; 12(6): 1169–76

    PubMed  CAS  Google Scholar 

  178. Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004 Oct 15; 101(8): 1835–42

    Article  PubMed  CAS  Google Scholar 

  179. Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008 Feb; 80(2): 127–32

    Article  PubMed  CAS  Google Scholar 

  180. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004 May 15; 103(10): 3684–8

    Article  PubMed  CAS  Google Scholar 

  181. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin’s lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997 Jul; 8(7): 675–80

    Article  PubMed  CAS  Google Scholar 

  182. Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin’s lymphoma. Blood 1990 Oct 1; 76(7): 1293–8

    PubMed  CAS  Google Scholar 

  183. Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008 May 15; 112(10): 2228–32

    Article  PubMed  CAS  Google Scholar 

  184. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008 Jan 10; 26(2): 204–10

    Article  PubMed  CAS  Google Scholar 

  185. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StIL) [abstract]. Blood 2008; 112(11): 2596

    Google Scholar 

  186. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008 Oct 20; 26(30): 4952–7

    Article  PubMed  Google Scholar 

  187. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995 Dec 7; 333(23): 1540–5

    Article  PubMed  CAS  Google Scholar 

  188. Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2008 Dec; 14(12): 1323–33

    Article  PubMed  Google Scholar 

  189. Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 2008 Oct; 22(5): 941–52, ix

    Article  PubMed  Google Scholar 

  190. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107(1): 265–76

    Article  PubMed  CAS  Google Scholar 

  191. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009 Jun; 8(6): 581–92

    Article  PubMed  CAS  Google Scholar 

  192. Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma 2008; 49Suppl. 1: 43–51

    Article  PubMed  CAS  Google Scholar 

  193. Ferreri AJ, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003 Jun 15; 21(12): 2407–14

    Article  PubMed  Google Scholar 

  194. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002 Dec 15; 20(24): 4643–8

    Article  PubMed  Google Scholar 

  195. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374(9700): 1512–20

    Article  PubMed  CAS  Google Scholar 

  196. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998 Mar; 16(3): 859–63

    PubMed  CAS  Google Scholar 

  197. Salaverria I, Perez-Galan P, Colomer D, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 2006 Jan; 91(1): 11–6

    PubMed  CAS  Google Scholar 

  198. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142(2): 210–21

    Article  CAS  Google Scholar 

  199. Sant M, Allemani C, De Angelis R, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008 Mar; 44(4): 579–87

    Article  PubMed  Google Scholar 

  200. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999 Apr; 36(2): 115–27

    PubMed  CAS  Google Scholar 

  201. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994 Oct 15; 84(8): 2726–32

    PubMed  CAS  Google Scholar 

  202. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995 Mar; 6(3): 257–62

    PubMed  CAS  Google Scholar 

  203. Oinonen R, Franssila K, Teerenhovi L, et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998 Feb; 34(3): 329–36

    Article  PubMed  CAS  Google Scholar 

  204. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009 Feb 1; 27(4): 511–8

    Article  PubMed  Google Scholar 

  205. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009 Mar 10; 27(8): 1209–13

    Article  PubMed  Google Scholar 

  206. Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008 Jul; 19(7): 1327–30

    Article  PubMed  CAS  Google Scholar 

  207. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009 Apr 30; 113(18): 4144–52

    Article  PubMed  CAS  Google Scholar 

  208. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989 Sep–Oct; 7(5): 365–80

    Article  PubMed  CAS  Google Scholar 

  209. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005 Mar 20; 23(9): 1984–92

    Article  PubMed  CAS  Google Scholar 

  210. Herold M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma (MCL) [abstract]. Blood 2004; 104(11): 584

    Google Scholar 

  211. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998 Dec; 16(12): 3803–9

    PubMed  CAS  Google Scholar 

  212. Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003 Dec 15; 98(12): 2630–5

    Article  PubMed  Google Scholar 

  213. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005 Oct 1; 23(28): 7013–23

    Article  PubMed  CAS  Google Scholar 

  214. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005 Apr 1; 105(7): 2677–84

    Article  PubMed  CAS  Google Scholar 

  215. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008 Oct 1; 112(7): 2687–93

    Article  PubMed  CAS  Google Scholar 

  216. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006 Sep; 17(9): 1418–23

    Article  PubMed  CAS  Google Scholar 

  217. Weigert O, Jurczak W, Von Schilling C, et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG [abstract]. J Clin Oncol 2006; 24(18 Suppl.): 7533

    Google Scholar 

  218. Smith MR, Zhang L, Gordon LI, et al. Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499 [abstract]. Blood 2007; 110(11): 389

    Google Scholar 

  219. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006 Oct 20; 24(30): 4867–74

    Article  PubMed  Google Scholar 

  220. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006 May 1; 24(13): 2105–12

    Article  PubMed  CAS  Google Scholar 

  221. O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 2005 Feb 1; 23(4): 676–84

    Article  PubMed  CAS  Google Scholar 

  222. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2005 Feb 1; 23(4): 667–75

    Article  PubMed  CAS  Google Scholar 

  223. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007 Jan; 18(1): 116–21

    Article  PubMed  CAS  Google Scholar 

  224. Barr P, Fisher R, Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer Invest 2007 Dec; 25(8): 766–75

    Article  PubMed  CAS  Google Scholar 

  225. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009 Mar; 20(3): 520–5

    Article  PubMed  CAS  Google Scholar 

  226. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009 May; 145(3): 344–9

    Article  PubMed  CAS  Google Scholar 

  227. Reeder CB, Witzig TE, Zinzani PL, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003) [abstract]. 2009 ASCO Annual Meeting Proceedings. J Clin Oncol 2009 May 20; 27(15 Suppl.): 8569

    Google Scholar 

  228. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009 Aug 10; 27(23): 3822–9

    Article  PubMed  CAS  Google Scholar 

  229. Witzig TE, Kaufmann SH. Inhibition of the phosphatidyl-inositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006 Jul; 7(4): 285–94

    Article  PubMed  Google Scholar 

  230. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004 Oct 15; 104(8): 2269–71

    Article  PubMed  CAS  Google Scholar 

  231. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005 Aug 10; 23(23): 5347–56

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Hillard Lazarus has received speaker’s honoraria from Genentech and Cephalon. Paul Barr has acted as a consultant to Millennium Pharmaceuticals and has received speaker’s honoraria from Cephalon. The other authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Ave, Wearn 341, Cleveland, Ohio, 44106, USA

    Paolo F. Caimi, Paul M. Barr, Nathan A. Berger &  Hillard M. Lazarus

Authors
  1. Paolo F. Caimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul M. Barr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathan A. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hillard M. Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hillard M. Lazarus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caimi, P.F., Barr, P.M., Berger, N.A. et al. Non-Hodgkin’s Lymphoma in the Elderly. Drugs Aging 27, 211–238 (2010). https://doi.org/10.2165/11531550-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11531550-000000000-00000

Keywords

Search

Navigation